Research in stone disease and minimally invasive surgery will also make its mark at the Society for Pediatric Urology annual meeting, which runs concurrently with the first 3 days of the AUA meeting.
New research about staged buccal mucosa graft urethroplasty and a study examining urethrotomy with mitomycin C for recurrent bladder neck contractures are among the key research in trauma/reconstruction being presented at the 2014 AUA annual meeting.
At the 2014 AUA annual meeting, look for the AUA to focus on many of its 2014 legislative priorities.
Research in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
Urologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.